Just got the news. This is a disaster. Only the non-colorectal group show a difference and nothing to party about: 36% vs 22% this is not even a 1 time reduction, this is a 0.39 time only, do not count with an FDA approval for this.
Before the company combine groups after the facts. Now they are dividing the groups, calling one arm of the study a subgroup, and they did not plan for this subgroup. Simply, they are trying to save face out of anything in the data.
The "colorectal" group is the one with more chances of infections, then the "non-colorectal" group is the one that they are pandering as a 39% reduction in infections. Good trick, but it does not work.
And the secondary endpoints are non impressive at all, except that they show an abismal failure: no reduction in mortality, no reduction in antibiotic days, no reduction in length of stay, no reduction of ICU days.
Whoever has a profit: take it. A loss: accept it. everybody out the street has spoken. A good short play ( I do not short ), in one week this will be at $1.00. |
